Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Transplantation and cellular therapy·2026
Same author

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026
Same author

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent <i>IDH1</i> mutation.

Blood neoplasia·2026
Same author

Management and risk mitigation strategies for <i>FLT3</i>-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.

Leukemia & lymphoma·2026
Same author

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Blood·2026

Related Experiment Video

Updated: Jun 27, 2026

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
07:53

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter

Published on: April 17, 2026

Pegasparaginase: where do we stand?

Amer Zeidan1, Eunice S Wang, Meir Wetzler

  • 1Roswell Park Cancer Institute, Department of Medicine, Buffalo, New York 14263, USA.

Expert Opinion on Biological Therapy
|December 10, 2008
PubMed
Summary

Pegylated asparaginase (PEG-ASP) offers a safer alternative to unmodified E. coli asparaginase (EC-ASP) for acute lymphoblastic leukemia (ALL) treatment. PEG-ASP reduces hypersensitivity and antibody development, improving patient outcomes.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Unmodified Escherichia coli asparaginase (EC-ASP) is effective for acute lymphoblastic leukemia (ALL) but causes toxicities like hypersensitivity and neutralizing antibodies.
  • Frequent administration of EC-ASP is required, limiting its clinical utility.

Purpose of the Study:

  • To discuss the pharmacology, pharmacokinetics, clinical trial results, and side effects of pegylated asparaginase (PEG-ASP).
  • To highlight PEG-ASP as an improved alternative to EC-ASP for ALL management.

Main Methods:

  • Review of clinical trial data and pharmacological studies on PEG-ASP.
  • Comparison of PEG-ASP with unmodified EC-ASP regarding efficacy, safety, and immunogenicity.

Main Results:

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Experiment Videos

Last Updated: Jun 27, 2026

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
07:53

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter

Published on: April 17, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

  • PEG-ASP demonstrates a prolonged half-life and decreased immunogenicity compared to EC-ASP.
  • Clinical trials confirm the efficacy, safety, and tolerability of PEG-ASP in pediatric and adult ALL patients.

Conclusions:

  • PEG-ASP is a viable and improved therapeutic option for managing acute lymphoblastic leukemia.
  • PEG-ASP overcomes the limitations of EC-ASP, offering better safety and tolerability profiles.